Legend Biotech Corp

Legend Biotech Corporation is a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR-T) therapy for multiple myeloma (MM). The company also has earlier-stage autologous CAR-T candidates targeting various cancers, and allogeneic gamma delta CAR-T and CAR-NK candidates targeting B-cell maturation antigen (BCMA) for MM in investigator-initiated Phase 1 trials in China. It has a collaboration and license agreement with Janssen Biotech, Inc. for cilta-cel, and a license agreement with Novartis Pharma AG for CAR-T therapies targeting delta-like ligand protein 3. Founded in 2014, Legend Biotech is headquartered in Somerset, New Jersey.